Navigation Links
Failure of Iclusig, Ariad’s Pharmaceutical Drug, No Surprise to CBCD
Date:10/20/2013

Rochester, NY (PRWEB) October 20, 2013

The failure of Ariad Pharmaceutical’s leukemia drug, Iclusig is no surprise to the CBCD. If top management at Ariad, and/or their investors, had turned to the CBCD, the Center would have told them that the chance of completing a successful clinical trial was almost zero.

What’s the argument? The productivity crisis in pharmaceutical R&D.

Iclusig was designed to target one specific molecule. However, like every drug, it impacts more than the specific molecule it was designed to target. When a drug impacts the ‘other’ molecules, it causes adverse reactions, or side effects. This was clearly the case in the development of Iclusig because in this case, some of the ‘other’ molecules were actually known.

As the author of an article published in February, 2013 in the formulary management journal P & T wrote, “The primary target (of Iclusig) is Bcr-Abl, an abnormal tyrosine kinase that is expressed in CML and Ph+ ALL (2).” If one carefully notes, however, the drug also “selectively blocks other tyrosine kinases, including FLT3, RET, KIT, and the members of the fibroblast growth factor receptor (FGFR) and platelet-derived growth factor (PDGFR) families (2).”

What kind of adverse reactions resulted from Iclusig’s impact on the ‘other’ molecules?

The answer is frightening. “Serious and fatal cases of arterial thrombosis (the formulation of a blood clot) and liver injury have occurred during treatment… cardiovascular, cerebrovascular, and peripheral vascular thrombosis, including fatal myocardial infarction (MI) (heart attack) and stroke have occurred in treated patients (2).”

In fact, because of these dangerous adverse reactions, “Ariad Pharmaceuticals Inc. abruptly terminated a pivotal clinical trial of its leukemia drug … a move that raised new safety questions and sent the company’s shares plunging more than 40 percent (1).”

Inclusig is
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. NIH media availability: Protein linked to increased risk of heart failure and death in older adults
2. Heart Failure Society of America Annual Meeting To Feature Several Satellite Symposia
3. A new treatment for kidney disease-associated heart failure?
4. Blocking digestive enzymes may reverse shock, stop multiorgan failure
5. Galectin-3 Assessed as a Biomarker of Heart Failure: Key Clinical Trial Findings Published by Dove Medical Press
6. At Three Months Post Launch, Two-Thirds of Surveyed U.S. Rheumatologists Believe that Initiations of Pfizers Xeljanz in the Rheumatoid Arthritis Treatment Algorithm Will Occur Following at Least Two Biologic Failures
7. SynCardia Total Artificial Heart Bridges Mother of Four with Congenital Heart Defect & Biventricular Heart Failure to Transplant
8. The Prevention of Heart Failure
9. Center Of Reproductive Medicine Participates In The Thrive-IVF Research Study To Help Improve Pregnancy Success Rates And Outcomes In Women With A History Of Repeated In Vitro Fertilization (IVF) Failures
10. Houston Fertility Institute Participates In The Thrive-IVF Research Study To Help Improve Pregnancy Success Rates And Outcomes In Women With A History Of Repeated In Vitro Fertilization (IVF) Failures
11. Celladon Corporation Announces Publication of Long Term Follow-Up Results from the MYDICAR CUPID 1 Trial in Advanced Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... , July 28, 2015 /PRNewswire/ - Aeterna Zentaris ... announced that it has granted to German life ... the development and commercialization of biotechnology (collectively, the ... recombinant oral allogenic tumor vaccine technology (the "Technology"), ... prostate cancer which is ready to enter a ...
(Date:7/27/2015)... July 27, 2015  Amgen (NASDAQ: AMGN ) ... financial results on Thursday, July 30, 2015, after the ... be followed by a conference call with the investment ... from Amgen will be Robert A. Bradway , ... Amgen,s senior management team. Live audio of ...
(Date:7/27/2015)... (PRWEB) , ... July 27, 2015 , ... Production of ... over the past few years in the EU. For instance, it surpassed the EUR ... EUR 92 million mark in 2010. Germany is a major producer, while Italy is ...
(Date:7/27/2015)... ... July 27, 2015 , ... ... network Monday. The venture will bring the world’s most efficient gas dissolution technology ... equipment and technologies to both the industrial and municipal markets. With offices located ...
Breaking Biology Technology:Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 3Amgen Announces Webcast of 2015 Second Quarter Financial Results 2High Tenacity Filament Yarn of Viscose Rayon Consumption to Grow Swiftly in the EU, Forecasts BAC Reports in New Study Available at MarketPublishers.com 2BlueInGreen Brings Water Treatment Technology to Florida 2
... , BOSTON, Oct. 19 There is increasing evidence ... the world,s six billion humans, and animal populations, with ... contend with a disease,s rapid appearance and change, e.g., ... of Replikins Ltd.,s demonstration that Replikins(TM) chemically synthesized vaccines ...
... (Nasdaq: NTII ) ("NTI") announced today it has submitted ... NTI intends to file a Form 25 with the Securities ... to effect the voluntary delisting of its common stock from ... pursuant to a Plan of Complete Liquidation and Dissolution at ...
... Product Portfolio , ROCKVILLE, Md., Oct. 19 OriGene ... Inc., a provider of cutting-edge multiplex assays for the ... profiling assays and testing services, and DNA and RNA ... in the bio-medical research industry by expanding the scope ...
Cached Biology Technology:New Non-Biological Synthetic Replikins(TM) Vaccines Shown to Be Effective and Fast; WorldVaccines(TM), Ltd Formed for Testing and Distribution 2New Non-Biological Synthetic Replikins(TM) Vaccines Shown to Be Effective and Fast; WorldVaccines(TM), Ltd Formed for Testing and Distribution 3OriGene Technologies Acquires Marligen Biosciences 2
(Date:7/9/2015)... July 9, 2015  Synaptics Inc. (NASDAQ: ... human interface solutions, today announced a new ... fully hardware encapsulated fingerprint sensor and matching ... is literally off the grid, isolating fingerprint ... within the fingerprint sensor to provide ultimate ...
(Date:7/8/2015)... 8, 2015  Trovagene, Inc. (NASDAQ: TROV ... announced the launch of a study that aims ... Monitoring℠ (PCM) technology for predicting response to treatment ... combination of the novel immunotherapy agents Yervoy® (ipilumumab), ... inhibitor. The 50-patient study will be led by ...
(Date:7/7/2015)... , July 7, 2015  Based on ... Frost & Sullivan recognizes Credence ID, LLC with ... Entrepreneurial Company of the Year Award. Credence ID ... aid in its mission of offering enrollment and ... globally. As Credence ID was formed by experts ...
Breaking Biology News(10 mins):Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5
... at The Schepens Eye Research Institute have discovered that ... in the eye and other parts of the body ... body's immune response and protect delicate tissues that cannot ... believe that this discovery may ultimately help in the ...
... II, the Korean War, and the Vietnam War are more ... men who are non-combat veterans or non-veterans, according to a ... of Cardiovascular Disease, Epidemiology and Prevention. , "Combat veterans ... opposed to never drinkers than non-veterans, and 1.6 times more ...
... North America to Mexico, monarch butterflies are known to ... guide to help them keep to a straight and ... have remained a mystery. , Now, researchers, led by ... Sauman of the Czech Academy of Sciences and Adriana ...
Cached Biology News:A protein in the eye may prevent immune response and protect eyes from disease 2Male Combat Veterans Rank High In Heart Disease Risk 2How monarch butterflies are wired for navigation 2
... are uniquely positioned to help ... competitive environment. Invitrogens experts employ ... purify, and characterize proteins that ... Activity Assays, X-ray Crystallography, NMR ...
albumin from bovine serum (BSA), fluorescein conjugate...
L1 Protein of Human Papilloma Virus Purified Anti-Viral-transformed cells clone CAMVIR-1, Isotype Mouse IgG 2a , 0.1 mg Consult technical datasheet for details....
... Cary 50 Microplate Reader accessory ... per analysis by extending the ... award-winning Cary 50 instruments. Use ... 384 samples in microlitre volumes, ...
Biology Products: